Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317637 · ClinicalTrials.gov registry record
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
A clinical trial of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
- Active
- Registry status
- 18
- Enrollment target
- 3
- Study locations
NCT05317637 is a study of Osteogenesis Imperfecta that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 18 participants, below the 160-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05317637, a study of Osteogenesis Imperfecta, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.
Conditions Studied
Study Locations (3)
California
- University of California Los Angeles - Los Angeles
Maryland
- Kennedy Krieger Institute / Hugo W. Moser Research Institute - Baltimore
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2027-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05317637
The ClinicalTrials.gov registry entry for NCT05317637 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (89% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 0 interventions.
NCT05317637 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT05317637 about?
NCT05317637 is a clinical study titled "Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708". Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 ...
What is the current status of trial NCT05317637?
This trial is currently active not recruiting. The enrollment target is 18 participants. The study started on 2022-08-01. Estimated completion is 2027-09-01.
What conditions does trial NCT05317637 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta.
Who is sponsoring clinical trial NCT05317637?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317637 being conducted?
This trial has 3 study locations across California, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
BBD Longitudinal Study of Osteogenesis Imperfecta
RECRUITING
-
Setrusumab vs Placebo for Osteogenesis Imperfecta
ACTIVE NOT RECRUITING · Phase 2
-
Urinary Biomarkers of OI Pathobiology
ACTIVE NOT RECRUITING
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.